Patent application number | Description | Published |
20090029946 | Aqueous oral solution of bisphosphonic acid - The present invention relates to stable aqueous oral formulation of bisphosphonic acid or its pharmaceutically acceptable salts. More particularly, the present invention relates to stable aqueous oral formulation of alendronate sodium. The present invention also relates to a process for the preparation of stable aqueous oral formulation of alendronate sodium. | 01-29-2009 |
20090202633 | Extended release formulations of guaifenesin - The present invention relates to extended release formulations comprising expectorant. More particularly, the present invention relates to extended release formulations comprising guaifenesin. The present invention also relates to a process for the preparation of extended release formulations comprising guaifenesin. | 08-13-2009 |
20090312547 | PROCESS FOR PREPARATION OF ROSUVASTATIN CALCIUM FIELD OF THE INVENTION - The present invention relates to an improved process for preparing (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium of Formula (I). | 12-17-2009 |
20100048899 | PROCESS FOR PREPARING ROSUVASTATIN CALCIUM - The present invention relates to an improved process for preparing Rosuvastatin calcium of Formula I. | 02-25-2010 |
20100056797 | Process for the Preparation of Irbesartan - The present invention relates to an improved process for the preparation of 2-n-butyl-3-[[2′-(1H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]-1,3-diazaspiro[4.4]non-1-en-4-one (Irbesartan) | 03-04-2010 |
20100076047 | Amorphous 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-p- ropanol phosphate salt - The present invention relates to a novel amorphous form of 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol phosphate (Carvedilol dihydrogen phosphate) of Formula (I), and a process for the preparation thereof. | 03-25-2010 |
20100125142 | PROCESS FOR PREPARING AN OPTICALLY ACTIVE PROTON PUMP INHIBITOR - An improved process for the preparation of (S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole of Formula I, (I) with high enantiomeric excess from racemic mixture. | 05-20-2010 |
20100137592 | PROCESS FOR PREPARING PURINE DERIVATIVE - A process for the preparation of famciclovir a compound of Formula (I) and its intermediates. | 06-03-2010 |
20100190982 | PROCESS FOR THE PREPARATION OF LAMIVUDINE FORM I - The present invention provides a process for preparing a stable crystalline solid of Lamivudine polymorphic Form I, which does not change to Form II during storage and pharmaceutical unit operations. | 07-29-2010 |
20110206761 | STABLE DOSAGE FORMS OF ANTIHYPERTENSIVE AGENTS - The technical field of the present invention relates to stable solid dosage form comprising combination of antihypertensive agents. More particularly, the present invention relates to stable solid dosage form comprising combination of angiotensin converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) and calcium channel blocker (CCB). | 08-25-2011 |
20110311625 | Solid dosage forms of fenofibrate - An improved solid dosage form of fenofibrate which exhibits improved dissolution properties leading to increased bioavailability of fenofibrate. A novel core-shell approach to the composition is provided as well as a process for the preparation of the improved solid dosage forms. | 12-22-2011 |
20120149905 | PROCESS FOR THE MANUFACTURE OF ROSUVASTATIN CALCIUM USING CRYSTALLINE ROSUVASTATIN ETHYL ESTER - The present invention relates to an improved process to prepare Rosuvastatin calcium of Formula (I), with good quality. Further, the present invention also relates to a crystalline polymorphic form of Rosuvastatin ethyl ester. | 06-14-2012 |
20120157683 | PROCESS FOR THE PREPARATION OF DUTASTERIDE - The present invention provides an improved process for the preparation of Dutasteride (I) which comprises: (i) reacting 4-aza-5α-androst-1-en-3-one-17β-carboxylic acid (VII), Formula VII with sulfonic acid anhydride (RSO | 06-21-2012 |
20120178810 | Extended release formulation of an antiepileptic agent - The present invention relates to an extended release formulation of an antiepileptic agent. More particularly, the present invention relates to an extended release formulation of divalproex sodium. The present invention also relates to a process for the preparation of extended release formulation of divalproex sodium. | 07-12-2012 |
20130108701 | Solid Dosage Forms of Antipsychotics | 05-02-2013 |
20130123502 | NOVEL PROCESS FOR THE PREPARATION OF SOLIFENACIN SUCCINATE - The present invention relates to a process for the preparation of Solifenacin succinate by condensing a compound of formula (IVb) with (RS)-3-quinuclidinol, wherein, R represents methyl, ethyl, isopropyl; to produce a diastereomeric mixture of (1S)-3,4-dihydro-1-phenyl-2(1H)-isoquinolinecarboxylic acid (3RS)-1-azabicyclo[2.2.2]oct-3-yl ester, which is treated with succinic acid in a solvent or mixture of solvents to produce optically pure Solifenacin succinate, Formula (X). | 05-16-2013 |
20130123537 | PROCESS FOR THE PREPARATION OF LACOSAMIDE - The present invention relates to an improved process for the preparation of Lacosamide of Formula (I), comprising: O-methylating a compound of Formula (V) or a compound of Formula (XX) or a compound of Formula XXII; in the presence of a methylating agent and a base to produce Lacosamide of Formula (I). | 05-16-2013 |
20130144067 | PROCESS FOR THE PREPARATION OF VALSARTAN - The present invention relates to a process for the preparation of pure Valsartan (I) substantially free from impurities of formulae (Ia), (Ib), and (Ic), which comprises: (i) condensing 2-(4′-bromomethylphenyl)benzonitrile of formula (II) with L-valine methyl ester hydrochloride of formula (V) in the presence of a base in a solvent to produce N-[(2′-cyanobiphenyl-4-yl)methyl]-(L)-valine methyl ester of formula (VI); (ii) treating the compound VI of step (i) with acid followed by treating with base to produce pure compound VI substantially free from dimeric impurity of formula (Via); (iii) reacting the pure compound of formula (VI) with n-valeryl chloride in the presence of a base to produce pure N-valeryl-N-[(2′-cyanobiphenyl-4-yl)methyl]-(L)-valine methyl ester (VII) substantially free from alkene impurity of formula (Vila); (iv) reacting the compound of formula (VII) with trialkyltin chloride and a metal azide in a solvent at a reflux temperature to produce N-(1-oxopentyl)-N-[[2′-(2-tributyltinte-trazol-5-yl)-(1,1′-biphenyl)-4-yl]methyl]-(L)-valine methyl ester of formula (VHIb) free from thermal degradation impurity (Villa); (v) hydrolyzing the compound of formula (VHIb) in the presence of alkaline conditions to produce Valsartan (I). | 06-06-2013 |